MARKET

ARDX

ARDX

Ardelyx
NASDAQ
4.410
-0.110
-2.43%
After Hours: 4.400 -0.01 -0.23% 19:39 07/18 EDT
OPEN
4.560
PREV CLOSE
4.520
HIGH
4.650
LOW
4.370
VOLUME
3.25M
TURNOVER
--
52 WEEK HIGH
7.18
52 WEEK LOW
3.210
MARKET CAP
1.06B
P/E (TTM)
-19.4874
1D
5D
1M
3M
1Y
5Y
1D
Wedbush Sticks to Its Buy Rating for Ardelyx (ARDX)
TipRanks · 4d ago
This Small-Cap Stock Could 10x by 2030, But It’s Not for the Faint of Heart
Barchart · 4d ago
Weekly Report: what happened at ARDX last week (0707-0711)?
Weekly Report · 5d ago
Ardelyx Faces An Uphill Battle Despite Oral Arguments Set In XPHOZAH Appeal
Seeking Alpha · 07/08 14:05
Weekly Report: what happened at ARDX last week (0630-0704)?
Weekly Report · 07/07 10:18
Ardelyx: 'Hold' With Caution As Major Inflection Point Approaches
Seeking Alpha · 07/03 17:05
Ardelyx Secures $50 Million Loan Amendment
TipRanks · 07/03 13:18
BRIEF-Ardelyx Inc - Enters Into Fifth Amendment To Loan Agreement - SEC Filing
Reuters · 07/03 12:50
More
About ARDX
Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing first-in-class medicines. The Company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.

Webull offers Ardelyx Inc stock information, including NASDAQ: ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.